NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis $0.84 0.00 (-0.33%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$0.82 -0.02 (-1.94%) As of 05:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Imunon Stock (NASDAQ:IMNN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Imunon alerts:Sign Up Key Stats Today's Range$0.82▼$0.8550-Day Range$0.80▼$1.1452-Week Range$0.64▼$3.65Volume84,458 shsAverage Volume886,150 shsMarket Capitalization$12.24 millionP/E RatioN/ADividend YieldN/APrice Target$21.50Consensus RatingBuy Company OverviewImunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Read More… Imunon Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreIMNN MarketRank™: Imunon scored higher than 37% of companies evaluated by MarketBeat, and ranked 560th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingImunon has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImunon has only been the subject of 2 research reports in the past 90 days.Read more about Imunon's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($1.68) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Imunon's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.33% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Imunon has recently decreased by 15.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.33% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Imunon has recently decreased by 15.00%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Imunon this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for IMNN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is a decrease of -92% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.47% of the stock of Imunon is held by institutions.Read more about Imunon's insider trading history. Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNN Stock News HeadlinesImunon announces IMNN-001 abstract accepted for oral presentation at 2025 ASCOApril 22, 2025 | markets.businessinsider.comIMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual MeetingApril 21, 2025 | globenewswire.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 5, 2025 | Porter & Company (Ad)Imunon Stock Short Interest Report | NASDAQ:IMNN | BenzingaApril 20, 2025 | benzinga.comImunon files to sell 10M shares of common stock, warrantsApril 5, 2025 | markets.businessinsider.comIMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…March 28, 2025 | msn.comFDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatmentMarch 25, 2025 | msn.comImunon finalizes Phase 3 study design with FDA for IMNN-001March 25, 2025 | markets.businessinsider.comSee More Headlines IMNN Stock Analysis - Frequently Asked Questions How have IMNN shares performed this year? Imunon's stock was trading at $0.95 on January 1st, 2025. Since then, IMNN shares have decreased by 11.9% and is now trading at $0.8372. View the best growth stocks for 2025 here. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.03. Read the conference call transcript. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Imunon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), NVIDIA (NVDA), AT&T (T), AbbVie (ABBV) and Broadcom (AVGO). Company Calendar Last Earnings11/07/2024Today5/05/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNN CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$21.50 High Stock Price Target$29.00 Low Stock Price Target$14.00 Potential Upside/Downside+2,468.1%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-230.05% Return on Assets-128.98% Debt Debt-to-Equity RatioN/A Current Ratio2.30 Quick Ratio2.30 Sales & Book Value Annual Sales$500,000.00 Price / Sales24.48 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.59Miscellaneous Outstanding Shares14,621,000Free Float13,776,000Market Cap$12.24 million OptionableNot Optionable Beta1.94 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:IMNN) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.